Clinical trial of Gilead sciences drug Remdesivir in COVID-1
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
In a trial conducted by Gilead Sciences, evaluating 5-day and 10-day dosing durations of the drug in coronavirus patients, it was found that the administration of remdesivir drug in patients with a severe manifestation of Covid-19 showed improvement.

“The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery,” Anthony Fauci, the top US epidemiologist who oversaw the study.

• 5-day course of Remdesivir would achieve similar results as the 10-day course of the drug.
• Effectiveness of drug measured in terms of improvement in breathing increased level of oxygen support to hospital discharge.
• Patients had evidence of pneumonia and reduced oxygen levels that did not require mechanical ventilation at the time of study entry.
• Patients receiving remdesivir within 10 days of onset of Covid-19 symptoms had improved outcomes when compared to those who were treated after over 10 days of symptom onset.
• Nearly 50% of patients in the 5-day treatment showed clinical improvement in 10 days
10-day treatment group, it was 11 days to report improvement in health.
• More than half of patients in both treatment groups were discharged from the hospital by Day 14.

Remdesivir is not licensed or approved globally. Multiple studies are underway to access if the agent is a safe and effective mode of treatment for coronavirus. Experts have called for further research on the drug and its effectiveness.


Source: https://in.reuters.com/article/health-coronavirus-gilead-remdesivir/data-on-gilead-drug-raises-hopes-in-pandemic-fight-fauci-calls-it-highly-significant-idINKBN22B1WQ
S●●●●j P●●●●●l and 28 others like this21 shares
Like
Comment
Share